I see DT has given a response, for which I will pick the following in particular!
"... The doctors were reluctant to do XYZ. We solved the problem by moving the PET scan to after enrollement in the treatment arm ... but the trial was cancelled by the management at the time before this change came in action ..."
To me, this suggests there was a disconnect between RAC and clinicians who actually look after patients / who were going to do the recruiting. Doctors do not not just do what Industry wants - they need to have enough conviction that what is being proposed is right for their patient. The proposal itself should have been made following study of the processes, including how patients flow from A to B, and to C or back to A. In otherwords, the clinicians should have participated in the design of the trial.
Fitting an experimental drug into an existing workflow makes uptake easier. Changing the process and workflows is hard, but can be done, if the potential benefits seem to be significant. Were they convinced? No!
The lesson: RAC would do well to work more closely with practicing clinicians when designing, planning and even implementing these trials.
RAC Price at posting:
$1.18 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)